Donatella Pisaniello
Donatella Pisaniello has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Daniele Ferraro
From the Unita Operativa Complessa Hepato-biliary Surgery and Liver Transplant Centre, General Surgery and Woman's Health Department,Italy
3 shared publications - Giovanni Vennarecci
Cardarelli Hospital
3 shared publications - Marcello Di Martino
Department of Health Sciences, University of Piemonte Orientale, Novara, Italy; , Novara, Italy; Division of General Surgery, Azienda Ospedaliero Universitaria Maggiore della Carita, Novara, Italy, Italy
3 shared publications - Alfonso Terrone
Department of Hepatobiliary and Liver Transplantation Surgery, A.O.R.N. Cardarelli, 80128 Napoli, Italy
2 shared publications - Ciro Esposito
Federico II University of Naples
2 shared publications - Federica Falaschi
Hepatobiliary Surgery Department, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131 Naples, Italy
2 shared publications
Latest Publications
- Open Access
- 1 April 2023
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 32 (1) , 118-119
Systemic therapy with lenvatinib in advanced hepatocellular carcinoma: what to do in the case of a complete radiologic response?
- 1 April 2023
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 32 (1) , 118-119
Open AccessSystemic therapy with lenvatinib in advanced hepatocellular carcinoma: what to do in the case of a complete radiologic response?
- Open Access
Downstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes
Background: Locoregional therapies (LRTs) are commonly used to increase the number of potential candidates for liver transplantation (LT). The aim of this paper is to assess the outcomes of LRTs prior to LT in patients with hepatocellular carcinoma (HCC) beyond the listing criteria. Methods: In accordance with the PRISMA guidelines, we searched the Medline and Web of Science databases for reports published before May 2021. We included papers assessing adult patients with HCC considered for LT and reporting intention-to-treat (ITT) survival outcomes. Two reviewers independently identified and extracted the data and evaluated the papers. Outcomes analysed were drop-out rate; time on the waiting list; and 1, 3 and 5 year survival after LT and based on an ITT analysis. Results: The literature search yielded 3,106 records, of which 11 papers (1874 patients) met the inclusion criteria. Patients with HCC beyond the listing criteria and successfully downstaged presented a higher drop-out rate (OR 2.05, 95% CI 1.45–2.88, p < 0.001) and a longer time from the initial assessment to LT than those with HCC within the listing criteria (MD 1.93, 95% CI 0.91–2.94, p < 0.001). The 1, 3 and 5 year survival post-LT and based on an ITT analysis did not show significant differences between the two groups. Patients with HCC beyond the listing criteria, successfully downstaged and then transplanted, presented longer 3 year (OR 3.77, 95% CI 1.26–11.32, p = 0.02) and 5 year overall survival (OS) (OR 3.08, 95% CI 1.15–8.23, p = 0.02) in comparison with those that were not submitted to LT. Conclusions: Patients with HCC beyond the listing criteria undergoing downstaging presented a higher drop-out rate in comparison with those with HCC within the listing criteria. However, the two groups did not present significant differences in 1, 3 and 5 year survival rates based on an ITT analysis. Patients with HCC beyond the listing, when successfully downstaged and transplanted, presented longer 3 and 5-year OS in comparison with those who were not transplanted.
Open AccessDownstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes
Background: Locoregional therapies (LRTs) are commonly used to increase the number of potential candidates for liver transplantation (LT). The aim of this paper is to assess the outcomes of LRTs prior to LT in patients with hepatocellular carcinoma (HCC) beyond the listing criteria. Methods: In accordance with the PRISMA guidelines, we searched the Medline and Web of Science databases for reports published before May 2021. We included papers assessing adult patients with HCC considered for LT and reporting intention-to-treat (ITT) survival outcomes. Two reviewers independently identified and extracted the data and evaluated the papers. Outcomes analysed were drop-out rate; time on the waiting list; and 1, 3 and 5 year survival after LT and based on an ITT analysis. Results: The literature search yielded 3,106 records, of which 11 papers (1874 patients) met the inclusion criteria. Patients with HCC beyond the listing criteria and successfully downstaged presented a higher drop-out rate (OR 2.05, 95% CI 1.45–2.88, p < 0.001) and a longer time from the initial assessment to LT than those with HCC within the listing criteria (MD 1.93, 95% CI 0.91–2.94, p < 0.001). The 1, 3 and 5 year survival post-LT and based on an ITT analysis did not show significant differences between the two groups. Patients with HCC beyond the listing criteria, successfully downstaged and then transplanted, presented longer 3 year (OR 3.77, 95% CI 1.26–11.32, p = 0.02) and 5 year overall survival (OS) (OR 3.08, 95% CI 1.15–8.23, p = 0.02) in comparison with those that were not submitted to LT. Conclusions: Patients with HCC beyond the listing criteria undergoing downstaging presented a higher drop-out rate in comparison with those with HCC within the listing criteria. However, the two groups did not present significant differences in 1, 3 and 5 year survival rates based on an ITT analysis. Patients with HCC beyond the listing, when successfully downstaged and transplanted, presented longer 3 and 5-year OS in comparison with those who were not transplanted.
- Open Access
- 10 October 2022
- Published by Springer Nature
- p. 163-171
Downstaging Strategies Prior to Liver Transplantation
- 10 October 2022
- Published by Springer Nature
- p. 163-171
Open AccessDownstaging Strategies Prior to Liver Transplantation